Portola (PTLA) has two important approved breakthrough products and an investigational product having promising results on very difficult-to-treat cancers. Instead of soaring following the approval of its two drugs and the good results coming from the investigational third drug, Portola’s stock took several dives, which raised the eyebrows of many investors and motivated more shareholders to sell PTLA.

Let us see whether the firm deserves the negative bloggers’ claims that Portola’s management is incompetent, or deserves an upgrade by fairer analysts instead.

Portola’s approved . . .